Bryan Simpson

Bryan Simpson is a gene therapy expert currently working as a Scientist and Preclinical Team Lead at Latus Bio, a biotech company based in Philadelphia, Pennsylvania.12 With over 10 years of research experience in gene therapy and gene editing, Simpson has a strong background in developing targeted therapies for central nervous system (CNS) disorders.1

Education and Early Career

Simpson completed his PhD in Cell & Molecular Biology at the University of Pennsylvania School of Medicine from 2014 to 2023.1 During his doctoral studies, he worked in Dr. Beverly Davidson's Laboratory at The Children's Hospital of Philadelphia, focusing on CRISPR-Cas9 strategies for reducing mutant ATXN2 levels in neurological diseases.1

Research Experience

Throughout his career, Simpson has:

• Developed and optimized AAV-Cas9 systems for in vivo gene editing in the mouse brain1
• Evaluated the efficacy of AAV-Cas9 in SCA2 mice using various behavioral, molecular, and neuropathological techniques1
• Pioneered the use of nanopore long-read DNA sequencing for assessing AAV-Cas9 on-target gene editing outcomes1
• Collaborated with academic and biotechnology industry groups1

Professional Achievements

Simpson's accomplishments include:

• Obtaining research funding from the National Ataxia Foundation1
• Presenting his work at department seminars and national and international conferences1
• Supervising undergraduate research assistants and technicians1

Current Role

As a Scientist and Preclinical Team Lead at Latus Bio, Simpson is likely applying his extensive experience in gene therapy and CRISPR technology to develop innovative treatments for CNS disorders.12 His role involves leading preclinical research efforts, which are crucial in advancing potential therapies towards clinical trials.34

Bryan Simpson's LinkedIn profile can be found at linkedin.com/in/bryan-simpson-ba4994a0, reflecting his professional journey and expertise in the field of gene therapy.1